Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification

被引:70
作者
Gilbert, J. W. [1 ,2 ,3 ]
Wolpin, B. [3 ,4 ]
Clancy, T. [3 ,5 ]
Wang, J. [3 ,5 ,6 ]
Mamon, H. [3 ,7 ,8 ]
Shinagare, A. B. [1 ,2 ,3 ]
Jagannathan, J. [1 ,2 ,3 ]
Rosenthal, M. [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA
[3] Harvard Med Sch, Boston, MA USA
[4] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Dept Surg, Div Surg Oncol, 75 Francis St, Boston, MA 02115 USA
[6] Dana Farber Brigham & Womens Canc Ctr, Gastrointestinal Surg Ctr, Boston, MA USA
[7] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA
[8] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
关键词
pancreatic adenocarcinoma; borderline resectable; neoadjuvant therapy; staging criteria; CT; GEMCITABINE-BASED CHEMORADIATION; MARGIN-NEGATIVE RESECTION; NEOADJUVANT THERAPY; PREOPERATIVE GEMCITABINE; GADOXETATE DISODIUM; PATHOLOGICAL RESPONSE; HEAD ADENOCARCINOMA; REFORMATTED IMAGES; PHASE-II; CT;
D O I
10.1093/annonc/mdx180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Diagnostic imaging plays a critical role in the initial diagnosis and therapeutic monitoring of pancreatic adenocarcinoma. Over the past decade, the concept of 'borderline resectable' pancreatic cancer has emerged to describe a distinct subset of patients existing along the spectrum from resectable to locally advanced disease for whom a microscopically margin-positive (R1) resection is considered relatively more likely, primarily due to the relationship of the primary tumor with surrounding vasculature. Materials and methods: This review traces the conceptual evolution of borderline resectability from a radiological perspective, including the debates over the key imaging criteria that define the thresholds between resectable, borderline resectable, and locally advanced or metastatic disease. This review also addresses the data supporting neoadjuvant therapy in this population and discusses current imaging practices before and during treatment. Results: A growing body of evidence suggests that the borderline resectable group of patients may particularly benefit from neoadjuvant therapy to increase the likelihood of an ultimately margin-negative (R0) resection. Unfortunately, anatomic and imaging criteria to define borderline resectability are not yet universally agreed upon, with several classification systems proposed in the literature and considerable variance in institution-by-institution practice. As a result of this lack of consensus, as well as overall small patient numbers and lack of established clinical trials dedicated to borderline resectable patients, accurate evidence-based diagnostic categorization and treatment selection for this subset of patients remains a significant challenge. Conclusions: Clinicians and radiologists alike should be cognizant of evolving imaging criteria for borderline resectability given their profound implications for treatment strategy, follow-up recommendations, and prognosis.
引用
收藏
页码:2067 / 2076
页数:10
相关论文
共 74 条
[1]   Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement [J].
Abrams, Ross A. ;
Lowy, Andrew M. ;
O'Reilly, Eileen M. ;
Wolff, Robert A. ;
Picozzi, Vincent J. ;
Pisters, Peter W. T. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1751-1756
[2]   PORTAL-VEIN RESECTION IN PATIENTS UNDERGOING PANCREATICODUODENECTOMY FOR CARCINOMA OF THE PANCREATIC HEAD [J].
ALLEMA, JH ;
REINDERS, ME ;
VANGULIK, TM ;
VANLEEUWEN, DJ ;
DEWIT, LT ;
VERBEEK, PCM ;
GOUMA, DJ .
BRITISH JOURNAL OF SURGERY, 1994, 81 (11) :1642-1646
[3]   Neoadjuvant therapy in pancreatic adenocarcinoma: A meta-analysis of phase II trials [J].
Assifi, M. Mura ;
Lu, Xuyang ;
Eibl, Guido ;
Reber, Howard A. ;
Li, Gang ;
Hines, O. Joe .
SURGERY, 2011, 150 (03) :466-473
[4]   Tumoral and Nontumoral Pancreas: Correlation between Quantitative Dynamic Contrast-enhanced MR Imaging and Histopathologic Parameters [J].
Bali, Maria A. ;
Metens, Thierry ;
Denolin, Vincent ;
Delhaye, Myriam ;
Demetter, Pieter ;
Closset, Jean ;
Matos, Celso .
RADIOLOGY, 2011, 261 (02) :456-466
[5]   Pancreatic perfusion:: Noninvasive quantitative assessment with dynamic contrast-enhanced MR imaging without and with secretin stimulation in healthy volunteers -: Initial results [J].
Bali, Maria Antonietta ;
Metens, Thierry ;
Denolin, Vincent ;
De Maertelaer, Viviane ;
Deviere, Jacques ;
Matos, Celso .
RADIOLOGY, 2008, 247 (01) :115-121
[6]   Respiratory Motion Artifact Affecting Hepatic Arterial Phase MR Imaging with Gadoxetate Disodium Is More Common in Patients with a Prior Episode of Arterial Phase Motion Associated with Gadoxetate Disodium [J].
Bashir, Mustafa R. ;
Castelli, Patricia ;
Davenport, Matthew S. ;
Larson, Douglas ;
Marin, Daniele ;
Hussain, Hero K. ;
Jaffe, Tracy A. .
RADIOLOGY, 2015, 274 (01) :141-148
[7]   Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS) [J].
Bockhorn, Maximilian ;
Uzunoglu, Faik G. ;
Adham, Mustapha ;
Imrie, Clem ;
Milicevic, Miroslav ;
Sandberg, Aken A. ;
Asbun, Horacio J. ;
Bassi, Claudio ;
Buechler, Markus ;
Charnley, Richard M. ;
Conlon, Kevin ;
Cruz, Laureano Fernandez ;
Dervenis, Christos ;
Fingerhutt, Abe ;
Friess, Helmut ;
Gouma, Dirk J. ;
Hartwig, Werner ;
Lillemoe, Keith D. ;
Montorsi, Marco ;
Neoptolemos, John P. ;
Shrikhande, Shailesh V. ;
Takaori, Kyoichi ;
Traverso, William ;
Vashist, Yogesh K. ;
Vollmer, Charles ;
Yeo, Charles J. ;
Izbicki, Jakob R. .
SURGERY, 2014, 155 (06) :977-988
[8]   Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma [J].
Brown, Kimberly M. ;
Siripurapu, Veeriah ;
Davidson, Marson ;
Cohen, Steven J. ;
Konski, Andre ;
Watson, James C. ;
Li, Tiaynu ;
Ciocca, Vince ;
Cooper, Harry ;
Hoffman, John P. .
AMERICAN JOURNAL OF SURGERY, 2008, 195 (03) :318-321
[9]   Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement [J].
Callery, Mark P. ;
Chang, Kenneth J. ;
Fishman, Elliot K. ;
Talamonti, Mark S. ;
Traverso, L. William ;
Linehan, David C. .
ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) :1727-1733
[10]   FACTORS INFLUENCING SURVIVAL AFTER PANCREATICODUODENECTOMY FOR PANCREATIC-CANCER [J].
CAMERON, JL ;
CRIST, DW ;
SITZMANN, JV ;
HRUBAN, RH ;
BOITNOTT, JK ;
SEIDLER, AJ ;
COLEMAN, J .
AMERICAN JOURNAL OF SURGERY, 1991, 161 (01) :120-125